

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Mammograms may continue as long as a woman has a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem.

ELIGIBILITY


CONCURRENT COMPONENTS OF VISIT

DISPOSITION

Female or male with invasive breast cancer 5 years from date of diagnosis¹ and NED

SURVEILLANCE

- History and physical with clinical breast exam annually
- Screening mammogram annually²
- Assess for compliance with hormone therapy and assess for toxicities if appropriate



See evaluation for recurrence in **Breast Cancer – Invasive algorithm**

Continue survivorship monitoring

MONITORING FOR LATE EFFECTS

- Consider the following:
- Bone health³ (see **Breast Cancer Survivorship: Bone Health algorithm**)
 - Cardiac screening⁴
 - Patient education regarding symptoms, including radiation therapy complications, if appropriate
 - Sexual health/fertility
 - Fatigue assessment
 - Neuropathy assessment
 - Cognitive dysfunction assessment
 - Gynecological assessment if on tamoxifen
 - Lymphedema assessment

RISK REDUCTION/EARLY DETECTION

- Patient education, counseling, and screening:
- Lifestyle risk assessment⁵
 - Cancer screening⁶
 - HPV vaccination as clinically indicated (see **HPV Vaccination algorithm**)
 - Screening for Hepatitis B and C as clinically indicated (see **Hepatitis Screening and Management – HBV and HCV algorithm**)
 - Genetic screening (if not already done) (see **Genetic Counseling algorithm**)
 - Vaccinations⁷ as appropriate

Refer or consult as indicated

PSYCHOSOCIAL FUNCTIONING

- Assess for:
- Distress management (see **Distress Screening and Psychosocial Management algorithm**)
 - Body image
 - Financial stressors
 - Social support

NED = no evidence of disease

¹ Completion of all treatment with the exception of hormonal agents

² Consider tomosynthesis

³ All postmenopausal women (especially those on aromatase inhibitors) and premenopausal women on ovarian suppression

⁴ Consider use of Vanderbilt's **ABCDE's approach to cardiovascular health**

⁵ See **Physical Activity, Nutrition, and Tobacco Cessation** algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

⁶ Includes **cervical** (if appropriate), **colorectal, liver, lung, pancreatic, prostate** (if appropriate), and **skin cancer screening**

⁷ Based on **Centers for Disease Control and Prevention (CDC) guidelines**

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., ... Thurlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumors: Recommendations of an international expert panel. *Annals of Oncology*, 19(3), 420-432. doi:10.1093/annonc/mdm442
- Barcnas, C. H., Shafae, M. N., Sinha, A. K., Raghavendra, A., Saigal, B. Murthy, R. K., ... Arun, B. (2018). Genetic counseling referral rates in long-term survivors of triple-negative breast cancer. *Journal of the National Comprehensive Cancer Network*, 16(5), 518-524. doi:10.6004/jncn.2018.7002
- Centers for Disease Control and Prevention. (2018). *Recommended immunization schedule for adults aged 19 years or older, United States, 2018*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., ... Jemal, A. (2014). Cancer treatment and survivorship statistics, 2014. *CA: A Cancer Journal for Clinicians*, 64(4), 252-271. doi:10.3322/caac.21235
- Giordano, S. H., Booser, D. J., Murray, J. L., Ibrahim, N. K., Rahman, Z. U., Valero, V., ... Hortobagyi, G. N. (2002). A detailed evaluation of cardiac toxicity. *Clinical Cancer Research*, 8(11), 3360. Retrieved from <http://clincancerres.aacrjournals.org/content/8/11/3360.full#ref-list-1>
- Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., ... Pfister, D. G. (2000). American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. *Journal of Clinical Oncology*, 18(6), 1378-1391. doi:10.1200/JCO.2000.18.6.1378
- Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., ... Brown, S. (2003). American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *Journal of Clinical Oncology*, 21(21), 4042-4057. doi:10.1200/JCO.2003.08.017
- Ke, Y., Ng, T., & Chan, A. (2018). Survivorship care models for breast cancer, colorectal cancer, and adolescent and young adult (AYA) cancer survivors: A systematic review. *Supportive Care in Cancer*, 26(7), 2125-2141. doi:10.1007/s00520-018-4197-y
- Mayer, D. K., Nekhlyudov, L., Snyder, C. F., Merrill, J. K., Wollins, D. S., & Shulman, L. N. (2014). American society of clinical oncology clinical expert statement on cancer survivorship care planning. *Journal of Oncology Practice*, 10(6), 345-351. doi:10.1200/JOP.2014.001321
- National Comprehensive Cancer Network. (2019). *Breast cancer* (NCCN Guideline Version 1.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- O'Carrigan, B., Wong, M. H. F., Willson, M. L., Stockler, M. R., Pavlakakis, N., & Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. *Cochrane Database of Systematic Reviews*, 2017(10), CD003474. doi:10.1002/14651858.CD003474.pub4
- Reid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., ... Coleman, R. E. (2008). Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK expert group. *Cancer Treatment Reviews*, 34(1), S3-S18. doi:10.1016/j.ctrv.2008.03.007
- Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., ... Ganz, P. A. (2016). American cancer society/American society of clinical oncology breast cancer survivorship care guideline. *Journal of Clinical Oncology*, 34(6), 611-635. doi:10.1200/JCO.2015.64.3809
- Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., ... Ganz, P. A. (2016). American cancer society/American society of clinical oncology breast cancer survivorship care guideline. *CA: A Cancer Journal for Clinicians*, 66(1), 43-73. doi:10.3322/caac.21319
- Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Breast Cancer Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Carlos H. Barcenas, MD (Breast Medical Oncology)
Isabelle Bedrosian, MD (Breast Surgical Oncology)
Therese Bevers, MD (Clinical Cancer Prevention)
Gabriel N. Hortobagyi, MD (Breast Medical Oncology)
Kelly Hunt, MD (Breast Surgical Oncology)
Thoa Kazantsev, BSN, RN, OCN*
Jessica Leung, MD (Diagnostic Radiology – Breast Imaging)
Paula Lewis-Patterson, DNP, RN, NEA-BC (Cancer Survivorship)
Stacy Moulder, MD (Breast Medical Oncology)
Simona Shaitelman, MD (Radiation Oncology)
Debu Tripathy, MD (Breast Medical Oncology)
Vicente Valero, MD (Breast Medical Oncology)

* Clinical Effectiveness Development Team